Gleevec (STI-571) For Chronic Myeloid Leukemia
Imatinib mesylate (STI-571; Gleevec - Novartis), an oral tyrosine kinase inhibitor, has received accelerated approval from the FDA for treatment of all phases of chronic myeloid leukemia (CML) after interferon has failed....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Gleevec (STI-571) For Chronic Myeloid Leukemia
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1106
Article Code: 1106a
Date: June 11, 2001
Volume: 43
Pages: 49-50
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1106
Article Code: 1106a
Date: June 11, 2001
Volume: 43
Pages: 49-50
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)